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Abstract
Using the economic complexity methodology on data for disease prevalence in 195 coun-
tries during the period of 1990-2016, we propose two new metrics for quantifying the disease
space of countries. With these metrics, we analyze the geography of diseases and empiri-
cally investigate the effect of economic development on the health complexity of countries.
We show that a higher income per capita increases the complexity of countries’ diseases.
We also show that complex diseases tend to be non-ubiquitous diseases that are prevalent
in disease-diversified (complex) countries, while non-complex diseases tend to be non-ubiq-
uitous diseases that are prevalent in non-diversified (non-complex) countries. Furthermore,
we build a disease-level index that links a disease to the average level of GDP per capita of
the countries in which the disease is prevalent. With this index, we highlight the link between
economic development and the complexity of diseases and illustrate how increases in
income per capita are associated with more complex diseases.
Introduction
There is strong historical evidence that the wealth of nations is positively linked to the health
of their populations. Since the eighteenth century, economic development associated with
improvements in nutrition, access to sanitation, public health interventions, and medical inno-
vations such as vaccination, have contributed to the reduction of major infectious diseases, the
decline of premature death rates, and a longer life expectancy for children and adults in both
developed and developing countries [1–4].
Nevertheless, many significant health problems have emerged in concert with economic
development and technological modernization. Among them, stress, anxiety, sleep depriva-
tion, and depression are mental disorders that are more prevalent in high-income countries.
While they account for only 9% of the burden in low-income countries, this figure is 18% in
middle-income and 27% in high-income countries [5]. In OECD countries, a longer life expec-
tancy is coupled with a higher rate of chronic and long-term illnesses in older populations [6].
Industrialization has expanded the reach of existing food-related diseases and created new dis-
orders and addictions [7]. Industrialization also stimulates urbanization, the process of popu-
lation migration from rural areas to cities. This makes urban areas focal points for many
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emerging environmental and health hazards [8, 9]. Industrialization is also linked to occupa-
tional accidents and work-related diseases (e.g., work-related cancers, musculoskeletal disor-
ders, respiratory diseases, psycho-social problems, and circulatory diseases), which are
worldwide problems resulting in important losses for individuals, organizations and societies
[10–17]. From the above discussion, it becomes clear that economic development can affect
population health in a number of ways, both positive and negative.
To study the determinants of a country’s level of health, and in particular its link with eco-
nomic development, a number of indicators are routinely used to measure population health,
such as mortality, life expectancy or a set of morbidity measures (including incidence, preva-
lence, and disability adjusted life years). Those indicators share the common aim of summariz-
ing the burden of diseases, and allow cross-country comparison as well as comparison
between diverse diseases, health conditions, and risk factors. While there is evidence that the
amount of health or diseases in a country is linked with its economic development, little is
known about the impact of economic development on the disease composition or disease
structure of a country.
To disentangle the relationship between economic development and population health and
gain more insight on countries’ health level and co-occurence of diseases, we follow a holistic
approach and explore (a) the country-disease network, which places countries with similar
diseases close together, and (b) the disease space, i.e., the network representation of the co-
occurrence of diseases worldwide. In this way, we can capture disparate diseases and health
conditions, and their intricate relationships into a unified measure to study its link with eco-
nomic development.
The relatedness of diseases has been previously studied at the micro level; Goh et al. in 2007
[18], who derive disease networks linking gene co-occurrence in various disorders, and
Hidlago et al. in 2009 [19], who use phenotypic connections between diseases to derive a Phe-
notypic Disease Network (PDN). Similarly, we construct the disease space linking country co-
occurrence of diseases. In this setting, explaining why countries are sharing a similar structure
of diseases is less straightforward as the underlying causes of co-occurrences of diseases at the
country level are multiple. These countries might for instance share the same type of risk fac-
tors, environment, population characteristics or lifestyles, and similar health care systems.
Thus, when a country is affected by a disease located in the core of the disease space, many
other similar countries are also affected by this disease. Studying the structure of the disease
space and knowing where a country is located in the country-disease network is therefore a
useful tool to monitor the evolution of diseases and plan global health policies.
The country-disease network and the disease space reveal information about the income of
populations and their health-related habits, such as lifestyle and dietary habits [20, 21]. There are
also multiple reasons to expect countries’ disease structures to be associated with their ‘structural
transformations’ (i.e., the industrialization process by which economies diversify from agricul-
ture to manufacturing and services [22–26]), environmental performance [27–30], or health-
related policies [31–34], as these contribute to their health status and living standards [35, 36].
We develop a new metric called theHealth Complexity Index, HCI, that quantifies the dis-
ease space by assigning lower values to countries with diseases located at the periphery of the
disease space and higher values to countries with diseases located at the centre of the disease
space (the diseases themselves are characterized by the corresponding Disease Complexity
Index, DCI, with lower values assigned to diseases located at the periphery of the disease space
and higher values to diseases located at the centre of the disease space). The HCI measures the
composition of a country’s pool of diseases by combining information on the complexity of
diseases, i.e., the number of countries in which the diseases have prevalent cases (ubiquity) and
the disease-diversity of these countries (the number of disease types).
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In this view, disease complexity is different from a disease requiring a complex treatment
or a disease with complex causes i.e. a multi-factorial disease. Thus, in this paper, we use the
term complex disease to refer solely to the concept of disease complexity that measures instead
whether a disease is located in the densely connected core of the disease space i.e., whether
many other related diseases are present in many other countries.
We show that relatively high scores on the HCI indicate countries with complex diseases.
These high-complexity diseases tend to be prevalent in only a few disease-diversified countries,
while low HCI scores refer to countries with low-complexity diseases, that are diseases that
tend to be prevalent in only a few non-diversified countries.
Moreover, we show that complex countries (diseases) tend to be (prevalent in) richer coun-
tries, while countries (diseases) with a low HCI (DCI) tend to be (prevalent in) poorer coun-
tries. The descriptive analysis also shows that non-complex diseases tend to be communicable
diseases, while complex diseases tend to be non-communicable diseases for which personal
lifestyles and societal conditions associated with economic development are important deter-
minants [37–40].
To compute the HCI, we follow the economic complexity methodology, which was initially
applied to trade micro-data, measuring the amount of knowledge materialized in a country’s
productive structure [41]. Based on the ECI methodology, a number of recent contributions
explain economic development and growth as a process of information development and of
learning how to produce and export more diversified products [41–55]. Furthermore, [56]
have recently shown that countries exporting complex products tend to be more inclusive and
have lower levels of income inequality than countries exporting simpler products. In addition,
[57] find that countries with high intellectual quotient (IQ) populations produce and export
more sophisticated/complex products, while [58] shows that the Internet has a positive effect
on economic complexity. Adopting the economic complexity methodology, [59] compute a
knowledge complexity index with more than two million patent records for US metropolitan
areas between 1975-2010. They analyze the geography and evolution of knowledge complexity
in US cities and show that the most complex cities in terms of patents are not always those
with the highest rates of patenting. In addition, using citation data, they show that more com-
plex patents are less likely to be cited than simpler patents when the citing and cited patents
are located in different metropolitan areas.
The aim of this paper is fourfold: (i) to build two new metrics that quantify the disease space,
following the economic complexity methodology; (ii) to explore the link between countries’
health complexity and their economic performance using the new metrics and following
dynamic panel data analysis; (iii) to develop a disease-level index that links a disease to the aver-
age level of GDP per capita of the countries in which the disease is prevalent; (iv) to illustrate how
a country’s economic development is associated with changes in its disease composition and ver-
ify the relationship between economic development and health complexity at the disease level.
The remainder of the paper is structured as follows. Section ‘The country-disease network’
describes the data on disease prevalence and the construction of the country-disease network.
Section ‘Methods’ presents the methodology for constructing the disease space and computing
the HCI and the DCI. Section ‘The geography of complex diseases’ presents the results of the
structural analysis of the disease space, with a particular focus on the geography and evolution
of health complexity across countries and regions. Section ‘The effect of economic develop-
ment on health complexity’ empirically investigates the relationship between economic
development and health complexity using the HCI, data on GDP per capita, and potential
covariates. Section ‘Economic development and disease complexity’ introduces an index that
decomposes economic performance at the disease level. Finally, in Section ‘Conclusions’, we
offer some concluding remarks.
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The country-disease network
Data on diseases and injuries
Information on diseases and injuries comes from the Global Burden of Diseases (GBD) study
led by the Institute for Health Metrics and Evaluation (IHME), an independent population
health research centre at the University of Washington (UW Medicine) [60]. The GBD study
has an established reputation for providing comparable estimates of the prevalence of diseases
and injuries across the world [61].
We used the 2016 version of the GBD study, which collects and analyzes a continuous
stream of the most up-to-date data available from a wide variety of sources (administrative rec-
ords, randomized controlled trials, cohort studies, surveys, census, scientific literature, satellite
data, vital registration data) [62]. The dataset covers more than 300 diseases and injuries for
195 countries in the period of 1990-2016. S1 and S2 Tables list the countries and diseases/inju-
ries included in our dataset. The data are extracted into centralized databases to model inter-
nally consistent estimates for diseases, injuries, and risk factors, adjusting for bias,
standardizing for age and incorporating covariates [61, 63]. GBD data and their descriptive
analysis are publicly available through interactive tools and visualizations (https://vizhub.
healthdata.org/gbd-compare/). The development of GBD methods/estimates, including statis-
tical techniques for missing data, are discussed in [62, 64–66]. The GBD methodology is
reviewed and updated annually and is compliant with the Guidelines for Accurate and Trans-
parent Health Estimates Reporting (GATHER) [67].
As described in the methodological appendix of the GBD 2016 study (S1 Appendix), input
data and data sources are less detailed and numerous in some low-income countries, com-
pared to developed countries; however, GBD 2016 estimates take into account under- and/or
miss-reporting of data, adopting up-to-date error correction methods that improve the reli-
ability of the recent estimates.
We acknowledge that differences in the accuracy of disease classifications between devel-
oped and developing countries might influence the disease space, but as [68] show, this effect
probably explains an insignificant part of our results. The authors find that the incidence rate
of all-sites cancer increases with per capita income, even after controlling for improvement in
cancer detection. In other words, if higher incidence rates in developed countries were merely
due to improved cancer detection, the authors would have found a flat or even an inverted-U
relationship between per capita income and cancer incidence.
Diseases and injuries are grouped by causes. The broader classification of causes (level 1)
includes: (a) communicable, maternal, neonatal, and nutritional diseases such as HIV/AIDS
and sexually transmitted infections, respiratory infections and tuberculosis, enteric infections
(e.g., diarrheal diseases, typhoid fever), neglected tropical diseases (e.g. malaria, chagas disease)
and other infectious diseases (e.g. meningitis and acute hepatitis), maternal and neonatal dis-
orders (e.g., maternal abortion and miscarriage, ectopic pregnancy, maternal obstructed labor
and uterine rupture), nutritional deficiencies (e.g., protein-energy malnutrition, vitamin A,
iron, iodine deficiencies); (b) non-communicable diseases such as cancers, cardiovascular dis-
eases, chronic respiratory diseases, digestive diseases (e.g., cirrhosis, gastritis, pancreatitis),
neurological disorders (e.g., multiple sclerosis, epilepsy, Parkinson’s and Alzheimer’s diseases,
migraine), mental disorders (e.g., schizophrenia, anorexia nervosa and bulimia nervosa, con-
duct and hyperactivity disorders), substance use disorders (e.g., alcohol and drug use disor-
ders), diabetes, kidney diseases, skin diseases (e.g., dermatitis, bacterial skin diseases), sense
organ diseases (e.g., glaucoma, cataract, vision loss), musculoskeletal disorders (e.g., osteoar-
thritis, rheumatoid arthritis); (c) injuries such as transport injuries (e.g., pedestrian road inju-
ries, cyclist and motorcyclist road injuries), unintentional injuries (e.g., falls, poisonings,
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exposure to mechanical forces), self-harm and interpersonal violence (e.g., sexual violence,
conflict and terrorism, executions). In the remainder of the paper we use the word ‘disease’ to
refer to all diseases and injuries classified in the GBD study.
We use information for the most detailed level of causes in the GBD taxonomy (i.e., level 4,
and when there is no level 4 classification, we use level 3). For example, among the non-com-
municable diseases (level 1), neoplasms (level 2) include the following level 3 categories: lip
and oral cavity cancer, nasopharynx cancer, other pharynx cancer, esophageal cancer, stomach
cancer, colon and rectal cancer, liver cancer, gallbladder and biliary tract cancer, pancreatic
cancer, larynx cancer, etc. Then, liver cancer includes the following level 4 subcategories: liver
cancer due to hepatitis B, liver cancer due to hepatitis C, liver cancer due to alcohol use, liver
cancer due to non-alcoholic steatohepatitis (NASH), liver cancer due to other causes.
Two measures of disease prevalence are exploited: the rate of prevalence (number of cases
per 100,000 population) for all ages, and the age-standardized rate of prevalence to account for
the differences in age structures across countries. This is useful because relative over- or
under-representation of different age groups can obscure comparisons of age-dependent dis-
eases (e.g., ischemic heart disease or malaria) across populations.
The country-disease bipartite network
Instrumental to our analysis is the bipartite network mapping of countries and diseases. Bipar-
tite, or bi-modal networks are abundant in the scientific literature, with examples including
the city-tech knowledge network [59], the city-firm network [69], firm-projects networks [70],
predator-prey networks [71], plants-pollinator networks [72] etc. Here, we use data from the
2016 Global Burden of Diseases study that assessed the disease burden of countries in the
period of 1990 to 2016, and we generate an l × k country-diseases matrix E, were the matrix
element Ecd represents the number of cases of disease d per 100,000 population in country c.
The aforementioned matrix allows for the construction of an undirected, weighted country-
disease network by linking each disease to the countries with disease cases. These networks are
very dense, and in order to visually explore their structure, we apply the Dijkstra algorithm [73]
to extract a Maximum Spanning Tree (MST) that summarizes their structures. More precisely,
the MST, which is usually considered as the backbone of the network, is a connected subgraph
having l + k − 1 edges with the maximum total weight and without forming any loops.
In Fig 1 we illustrate the country-disease MST for 2016. From this MST, we can easily iden-
tify clusters of countries that are linked to specific types of diseases. The main node of the net-
work is caries in permanent teeth (disease cause number 682; see S2 Table for the list of
diseases). This disease is the most common disease across the world, as it is present in the
majority of countries. It is also the disease with the highest prevalence worldwide (2.44 billion
cases in 2016 [60]).
Methods
To calculate health complexity, we combine information on diseases prevalence and how com-
mon these diseases are across countries, following the economic complexity methodology, i.e.,
the formulas in the pioneering work of [49].
The relative disease disadvantage
In short, let us assume that we have disease information for l number of countries and k dis-
eases. With this information, we can fill an l × k diseases matrix E, so that matrix element Ecd is
country c’s information for disease d. If there is no information for disease d in country c, then
PLOS ONE Health complexity
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where Xcd is the number of cases of disease d per 100,000 population in country c.
Similar to the economic complexity methodology and the discussion in [44, 49, 56], we
claim that a country has a relative disease disadvantage in a disease when RDDcd� 1. In other
words, a country c has an RDD in disease d if the proportion of its cases in the country’s pool
Fig 1. Maximum spanning tree of the country-disease bipartite network. Countries are represented by yellow nodes, and diseases cover the following
categories: [A. ‘Communicable, maternal, neonatal, and nutritional diseases’] A.1 ‘HIV/AIDS and tuberculosis’, A.2 ‘Diarrhea, lower respiratory, and
other common infectious diseases’, A.3 ‘Neglected tropical diseases and malaria’, A.4 ‘Maternal disorders’, A.5 ‘Neonatal disorders’, A.6 ‘Nutritional
deficiencies’, A.7 ‘Other communicable, maternal, neonatal, and nutritional diseases’; [B. ‘Non-communicable diseases’] B.1 ‘Neoplasms’, B.2
‘Cardiovascular diseases’, B.3 ‘Chronic respiratory diseases’, B.4 ‘Cirrhosis and other chronic liver diseases’, B.5 ‘Digestive diseases’, B.6 ‘Neurological
disorders’, B.7 ‘Mental and substance use disorders’, B.8 ‘Diabetes, urogenital, blood, and endocrine diseases’, B.9 ‘Musculoskeletal disorders’; [C.
‘Injuries’] C.1 ‘Transport injuries’, C.2 ‘Unintentional injuries’, C.3 ‘Self-harm and interpersonal violence’, C.4 ‘Forces of nature, conflict and terrorism,
and executions and police conflict’. Data for 2016.
https://doi.org/10.1371/journal.pone.0244843.g001
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of all disease cases is higher than the proportion of disease d’s cases in the world’s pool of all
disease cases.
Using this threshold value, we obtain the l × kmatrix M, with matrix elementsMcd = 1 if
country c has an RDD in disease d, and zero otherwise. A visualization of the matrix M for this
dataset is shown in Fig 2, where a dark point indicates that country c has an RDD in a given
disease d. The matrix is sorted using the NODF algorithm [74], which highlights the existence
of countries that are very well diversified and countries that have an RDD only in a small set of
diseases.
In what follows, we assume that a disease d is prevalent in country c when RDDcd� 1.
The disease space
The clustering of countries and diseases in the MST of the country-disease network already
points towards relations in the prevalence of different diseases (Fig 1). To explore this further,
we construct the disease space, similar to the product-space introduced by [41].
Calculating the RDD for all country-disease pairs allows us to derive a matrix F, whose ele-
ments Fi,j define a proximity measure between all pairs of diseases. This proximity measure
reveals diseases that are present in tandem, or in other words, with F, we measure the proba-
bility that a country c, which has a relative disease disadvantage in disease i, also has a relative
disease disadvantage in disease j. The proximity measure is defined as:
Φi;j ¼ minfPrðRDDi � 1 j RDDj � 1Þ; PrðRDDj � 1 j RDDi � 1Þg; ð2Þ
where Pr(RDDi� 1 | RDDj� 1) is the conditional probability of having a relative disease dis-
advantage in disease i if you have a relative disease disadvantage in disease j. Using the mini-
mum of both conditional probabilities, we avoid issues of a rare disease being present in only
one country. Additionally, we make the resulting matrix F symmetric (see Fig 3). The proxim-
ity matrix is highly modular and its block structure reveals the presence of ‘communities’, i.e.,
groups of diseases that are expected to occur together.
Fig 2. Matrix representation of the links between countries and diseases. A visualization of this matrix for the year 2016, where a dark
point indicates that country c has an RDD in a given disease d. The matrix is sorted by row and column sums. While the existence of
countries that are very well diversified and countries that have a relative disease disadvantage only in a small set of diseases is clear, we
would like to note that contrary to applications of this methodology to country-export data, for the disease prevalence this matrix is not
clearly triangular (or nested).
https://doi.org/10.1371/journal.pone.0244843.g002
PLOS ONE Health complexity
PLOS ONE | https://doi.org/10.1371/journal.pone.0244843 January 7, 2021 7 / 35
Next, we map this matrix onto a network, where each disease is represented by a node and
every matrix element represents a weighted and undirected link. Similar to Fig 1, we start by
applying Dijkstra’s algorithm on matrix F which calculates the MST of the network. Following
the rationale of [41], we start from the strongest links that are not part of the MST and keep
adding links to the network until the average degree is four. The resulting network is a visual
representation of the disease space, which is shown in Fig 3.
From Fig 3, it is evident that in the disease space network, different disease categories are
clustered together and the network is heterogeneous and follows a core-periphery structure.
The external part of the network (the periphery) is mostly dominated by ‘communicable,
maternal, neonatal, and nutritional diseases’. On the other hand, the core of the network is
dominated by ‘non-communicable diseases’.
As reported by [19], disease prevalence, i.e., the number of times a particular disease is diag-
nosed, follows a heavy-tailed distribution. In this case, the economic complexity methodology
becomes a handy tool as it allows us to link a country to a particular disease only if it has a
Fig 3. The proximity matrix and the resulting disease space. The size of the nodes is proportional to their degree, i.e., the number of links. Disease
colors cover the following categories: [A. ‘Communicable, maternal, neonatal, and nutritional diseases’] A.1 ‘HIV/AIDS and tuberculosis’, A.2
‘Diarrhea, lower respiratory, and other common infectious diseases’, A.3 ‘Neglected tropical diseases and malaria’, A.4 ‘Maternal disorders’, A.5
‘Neonatal disorders’, A.6 ‘Nutritional deficiencies’, A.7 ‘Other communicable, maternal, neonatal, and nutritional diseases’; [B. ‘Non-communicable
diseases’] B.1 ‘Neoplasms’, B.2 ‘Cardiovascular diseases’, B.3 ‘Chronic respiratory diseases’, B.4 ‘Cirrhosis and other chronic liver diseases’, B.5
‘Digestive diseases’, B.6 ‘Neurological disorders’, B.7 ‘Mental and substance use disorders’, B.8 ‘Diabetes, urogenital, blood, and endocrine diseases’, B.9
‘Musculoskeletal disorders’; [C. ‘Injuries’] C.1 ‘Transport injuries’, C.2 ‘Unintentional injuries’, C.3 ‘Self-harm and interpersonal violence’, C.4 ‘Forces
of nature, conflict and terrorism, and executions and police conflict’. Data for 2016.
https://doi.org/10.1371/journal.pone.0244843.g003
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relative disease disadvantage. As was shown by [75], economic-complexity-based indices are
related to various dimensionality-reduction methods and are equivalent to a spectral clustering
algorithm. This allows the indices to be interpreted as vectors that determine distances between
nodes based on their similarity, which is a nice way to interpret the disease-space network. In
our case, we reduce the space of the various ways that diseases could be linked together, and
we are only interested in identifying links between diseases with a large probability of co-
occurrence.
We highlight that disease prevalence is starkly different to product exports that are used
in applications of the economic complexity methodology. Countries acquire capabilities over
time that enable them to develop more sophisticated products and increase the complexity
of their production. This process is a cumulative one, i.e., countries are constantly increasing
their product portfolio by developing new capabilities without loosing previously acquired
ones. In contrast, as countries become more developed, they are more effective at fighting dis-
eases, e.g., by using new treatments or vaccines and by improving the general hygiene of the
population. Therefore, the set of diseases in a country does not increase monotonically in
time, as new diseases are added and some diseases disappear. Thus, we expect our results to be
somehow different to findings based on export data, and the first hint is already provided by
the structure of Fig 2, which is less nested compared to similar figures in other applications of
economic complexity.
Health complexity index
From matrix M, similar to [49], we introduce the HCI as a measure of countries’ disease struc-
tures. To obtain the HCI, we first calculate the l × l square matrix ~M. In short, matrix ~M pro-
vides information about links connecting two countries c and c0, based on the disease cases in









where kc,0 = ∑d Mcdmeasures the diversification of country c in terms of its different diseases
i.e. the number of disease-types d for which a country c has an RDD, and kd,0 = ∑c Mcdmea-
sures the number of countries with an RDD in disease d i.e the ubiquity of disease d. If K is the
eigenvector of ~M associated with the second largest eigenvalue, then according to [48], the





As discussed in sub-section ‘The relative disease disadvantage’, the HCI is computed using
in Xcd the number of disease cases (according to cause levels 3 or 4) per 100,000 population for
195 countries and for 196 diseases. The time-period covered is from 1990 to 2016. With the
age-standardized data (see the discussion in subsection ‘Data on diseases and injuries’, we also
calculate the age-standardized health complexity index (AHCI) following the same formulas.
We use the two indices as alternative measures when checking the robustness of our results. It
should be noted here that the computation of the indices is based only on diseases for which a
country has an RDD in terms of disease prevalence (the incidence matrix of the bipartite net-
work linking countries to diseases, M, reflects whether or not a country has an RDD in a spe-
cific disease; see Fig 2).
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The disease complexity index
In a similar manner, but placing the spotlight on diseases rather than countries, we calculate
the Disease Complexity Index (DCI) in which the k × kmatrix ~M provides information about
links connecting two diseases d and d0, based on the number of countries in which both dis-
eases have cases. The DCI is computed using in Xcd the number of disease cases (according to
cause levels 3 or 4) per 100,000 population for 195 countries and for 196 diseases. The time-
period covered is from 1990 to 2016. With the age-standardized data (see the discussion in
subsection ‘Data on diseases and injuries’), we also calculate the age-standardized disease com-















Table 1 lists the five diseases with the highest and lowest DCI scores averaged over the
period of 1990-2016. Interestingly, we see that high-complexity diseases i.e diseases with the
highest DCI belong to disease sections that include multi-factorial diseases.
The computation of the indexes was performed using R version 4.0.0.
The geography of complex diseases
Ubiquity, diversity, and the HCI
In this subsection, we elaborate on the association of the HCI with the diversification of coun-
tries and ubiquity of diseases. Figs 4 and 5 provide additional information on where countries/
diseases are located in the disease space. From these figures, we can better understand the type
of health-related information captured by the economic complexity methodology, and we can
Table 1. List of the five diseases with the highest and lowest DCI values during the period of 1990-2016.
Code Disease name Disease section DCI
Highest DCI
459 Malignant skin melanoma Neoplasms 1.210
441 Colon and rectal cancer Neoplasms 1.170
502 Peripheral artery disease Cardiovascular diseases 1.169
456 Pancreatic cancer Neoplasms 1.159
533 Vascular intestinal disorders Digestive diseases 1.152
Lowest DCI
345 Malaria Neglected tropical diseases and malaria -2.045
350 African trypanosomiasis Neglected tropical diseases and malaria -1.978
370 Maternal obstructed labor and uterine rupture Maternal and neonatal disorders -1.957
358 Yellow fever Neglected tropical diseases and malaria -1.893
340 Tetanus Other infectious diseases -1.883
Notes: DCI: Disease Complexity Index; Average values for 1990-2016.
https://doi.org/10.1371/journal.pone.0244843.t001
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Fig 4. Average ubiquity, diversity, and the HCI. Left panel: Relationship between diversity and average ubiquity. The
diagram is divided into 4 quadrants defined by the empirical observed averages of diversity and average ubiquity; Right
panel: Relationship between diversity and HCI. The colors depict different income-regions of the world according to
World Bank’s classification. Data for 2016.
https://doi.org/10.1371/journal.pone.0244843.g004
Fig 5. Ubiquity, average diversity, and the DCI. Relationship between ubiquity and average diversity (left). Relationship
between average diversity and DCI. The colors depict different disease types. Data for 2016.
https://doi.org/10.1371/journal.pone.0244843.g005
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explore the way in which the economic complexity methodology can be interpreted as a spec-
tral clustering algorithm when applied to disease data [75, 76].
In Fig 4, the left panel shows the relationship between diversity and average ubiquity of
countries in terms of diseases. The different colors represent different income regions of the
world according to World Bank’s classification. The diagram is divided into 4 quadrants
defined by the empirical observed averages of diversity and average ubiquity. The upper left
quadrant refers to non-diversified countries with RDD in ubiquitous diseases. The upper right
quadrant depicts the diversified countries with RDD in ubiquitous diseases. The lower left
quadrant depicts non-diversified countries with RDD in non-ubiquitous diseases. The lower
right quadrant refers to the diversified countries with RDD in non-ubiquitous diseases.
The right panel in Fig 4 depicts a strong positive relationship between diversity and the
HCI (ρ = 0.8271 with a p-value < 10−48). High-HCI countries have many diseases with RDD
that tend to be prevalent in only few other disease-diversified countries. Portugal, Andorra,
and Norway are some examples of health-complex countries. On the other hand, low-HCI
countries have few diseases with RDD, which tend to be prevalent in only few other non-diver-
sified countries, e.g., Congo, Democratic Republic of the Congo, and Chad.
Fig 5 places the spotlight on diseases. The left graph shows the relationship between ubiq-
uity and average diversity of diseases. The right graph shows the relationship between DCI and
ubiquity. The two variables are not correlated: ρ = 0.0883 with a p-value = 0.2184. This implies
that ubiquity fails to be health-informative. The information provided by the two graphs sug-
gests that high-DCI diseases tend to be prevalent in only few disease-diversified countries.
These diseases are mostly non-communicable diseases such as ‘colon and rectum cancer’,
‘malignant skin melanoma’, and ‘pancreatic cancer’ (such diseases are located in the upper left
quadrant, left graph of Fig 5). On the other hand, low-DCI diseases tend to be prevalent in
only few non-diversified countries. These diseases are located in the lower left quadrant. Some
examples are ‘malaria’, ‘African typanosomiasis’, ‘maternal obstructed labor and utirine rup-
ture’, and they are typically communicable diseases. Diseases i.e with ubiquity above the aver-
age, include, on one side, ‘diarrheal diseases’, ‘appendicitis’, and ‘epilepsy’, which are more
present in non-diversified countries, and on the other side, ‘motorcyclist road injuries’,
‘chronic obstructive pulmonary disease (COPD)’ or ‘other neurological disorders’ which tend
to be more prevalent in diversified countries (See respectively lower and upper right quad-
rants, left graph of Fig 5).
The above descriptive findings imply that the HCI places countries on a one-dimensional
interval such that countries with many diseases (diversified countries) are close together and
countries with only few diseases (non-diversified countries) are far apart. Furthermore, the
(non-)diversified countries that tend to have non-ubiquitous diseases are (less) more health-
complex compared to the other (non-)diversified countries. For illustrative purposes Fig 6 dis-
plays the relationship between the average diversity and ubiquity of diseases for four selected
countries. The pool of diseases with RDD in Portugal, the country with the highest HCI in
2016, is composed of many diseases (125) that are prevalent almost exclusively in diversified
countries. These diseases are non-communicable diseases (80.80%) and injuries (16%), and
include the sixteen highest DCI diseases in 2016: ‘malignant skin melanoma, pancreatic can-
cer’, ‘colon and rectum cancer’, ‘vascular intestinal disorders’, ‘peripheral artery disease’, ‘gall-
bladder and biliary tract cancer’, ‘kidney cancer’, ‘Parkinson disease’, ‘mesothelioma’, ‘bladder
cancer’, ‘tracheal, bronchus, and lung cancer’, ‘Hodgkin lymphoma’, ‘multiple myeloma, ische-
mic stroke’, ‘atrial fibrillation and flutter’, ‘brain and nervous system cancer’. Portugal has a
RDD in only four communicable disease-types: ‘food-borne trematodiases’, ‘varicella and her-
pes zoster’, ‘upper respiratory infections’, and ‘HIV/AIDS resulting in other diseases’. On the
contrary, in the Democratic Republic of Congo, the country with the lowest HCI in 2016, two-
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thirds of the diseases are communicable, maternal, neonatal, or nutritional diseases amongst
the total of 57 diseases for which the country has an RDD. Those 57 diseases are non-ubiqui-
tous diseases and are only prevalent in other non-diversified countries. In comparison, Belize,
located in the upper left quadrant of Fig 4, counts 82 disease-types with RDD. These diseases,
of which 65% are non-communicable diseases and 11% injuries, are mostly ubiquitous and
prevalent in other non-diversified countries. While for diversified countries with RDD in
ubiquitous diseases (situated in the upper right quadrant of Fig 4), such as Turkmenistan, the
picture is the following; more than three-quarters of its 127 diseases with RDD, are ubiquitous
and non-communicable diseases, with the majority of those, being prevalent in other diversi-
fied countries.
For diseases, the dimensionality reduction perspective of the DCI places diseases that are
prevalent in more diversified countries close together and diseases that are prevalent in non-
diversified countries far apart. Moreover, the (non-)ubiquitous diseases in the former set of
diseases are relatively (more) less complex, while the (non-)ubiquitous diseases in the latter set
of diseases are relatively (less) more complex. Fig 7 presents the relationship between the aver-
age ubiquity and diversity for four selected diseases. ‘Malignant skin melanoma’ is the most
complex disease in 2016. As we can see in the upper left graph, the disease appears with an
RDD almost exclusively in highly diversified countries that have an RDD in more complex dis-
eases. Those 45 countries are mostly European countries with the highest HCI in 2016, and
other high-income countries including the United States, Canada, New Zealand, and Australia.
In contrast, ‘malaria’ is exclusively prevalent in 30 non-diversified countries that have an RDD
in non-complex diseases. Examples include the sixteen less-complex countries in 2016: Demo-
cratic Republic of the Congo, Congo, Chad, Central African Republic, Equatorial Guinea,
Liberia, Gabon, Guinea, South Sudan, Nigeria, Burkina Faso, Benin, Mozambique, Angola,
Sierra Leone, and Madagascar. In comparison, ‘motorcyclist road injuries’ is an ubiquitous
Fig 6. Ubiquity and average diversity of diseases in four selected countries. Relationship between ubiquity and
average diversity of diseases for which the country (respectively Belize, Turkmenistan, the Democratic Republic of
Congo and Portugal) has a Relative Disease Disadvantage (RDD). The colors depict different disease types. Data for
2016.
https://doi.org/10.1371/journal.pone.0244843.g006
PLOS ONE Health complexity
PLOS ONE | https://doi.org/10.1371/journal.pone.0244843 January 7, 2021 13 / 35
disease-type (81 countries have an RDD in this disease-type in 2016), mostly prevalent in more
diversified countries. While ‘appendicitis’ is an ubiquitous disease (it counts 95 countries with
RDD), that is more prevalent in non-diversified countries.
From Figs 4 and 5, we can see that high-HCI countries tend to be richer and high-DCI dis-
eases tend to be prevalent in higher-income countries. We develop further this point in the
next subsection.
The HCI by income group of countries and over time
Fig 8 shows the patterns of disease localization in the world’s economies, classified by the
World Bank into four income groups: ‘high’, ‘upper-middle’, ‘lower-middle’, and ‘low’. Dis-
eases in a region where more than half of the countries have an RDD� 1 are shown with black
nodes. It seems that high-income countries occupy the core, composed of ‘non-communicable
diseases’ such as ‘pancreatic cancer’, ‘Parkinson disease’, ‘ischemic stroke’, and injuries such as
‘falls’, ‘poisonings’ and ‘other exposure to mechanical forces’. On the other side of the spec-
trum, low-income countries tend to have an RDD in ‘communicable, neonatal, maternal and
nutritional diseases’ that lie in the periphery of the disease space, such as ‘diarrheal diseases’,
‘encephalitis’, and ‘malaria’. Most of the communicable diseases for which low-income coun-
tries have an RDD� 1 also appear in the periphery (for example, ‘Turner syndrome’, ‘neural
tube defects’, and ‘pyoderma’). Examples of injuries for which low-income countries have an
RDD include ‘venomous animal contact’ and ‘sexual violence’, which again appear in the
periphery of the disease space.
Previous research shows that there is a strong association between income and indicators
of population health such as life expectancy and child mortality. There are various channels
through which economic development can stimulate health improvements, for example, via
its effect on nutrition (which in turn leads to better resistance to bacterial diseases and faster
Fig 7. Average ubiquity and diversity of countries in four selected diseases. Relationship between average ubiquity
and diversity of countries with RDD in respectively; malignant skin melanoma, motorcyclist road injuries, malaria,
and appendicitis. The colors depict different income-regions of the world according to World Bank’s classification.
Data for 2016.
https://doi.org/10.1371/journal.pone.0244843.g007
PLOS ONE Health complexity
PLOS ONE | https://doi.org/10.1371/journal.pone.0244843 January 7, 2021 14 / 35
recovery from illnesses), as well as through greater labor market participation, worker produc-
tivity, investment in human capital, investment in public and private health services, savings,
fertility, transportation infrastructure, lifestyle habits, and innovation in medical treatments
[3, 37, 77–85]. For a review of the empirical evidence see [86].
Fig 8. Localisation of diseases for different income-regions of the world. A: High income, B: Upper-middle income,
C: Lower-middle income, D: Low income. Diseases in an income-region where more than half of the countries
belonging to this region have an RDD are shown with black nodes in the disease space network. Data for 2016.
https://doi.org/10.1371/journal.pone.0244843.g008
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There have also been negative impacts from development, as shown by increases in injuries
(e.g., road injuries), heart diseases (e.g., coronary artery disease), and diseases resulting from
environmental degradation [87]. Due to modern lifestyles, populations in developed countries
are bound to engage in some unhealthy behaviors that lead to health-related problems like
obesity, hypertension, diabetes, cancers, and respiratory diseases. These non-communicable
diseases, called ‘diseases of affluence’ or ‘diseases of civilization’ correspond to more diversified
and less ubiquitous diseases in our analysis. It has been shown that they are dominant in all
middle and high income countries and that their main determinant is economic development
[17, 20, 37, 88, 89–91].
On the other side, the so-called ‘diseases of poverty’ include mostly communicable diseases
that largely result from and contribute to human impoverishment. In our analysis, these dis-
eases are non-complex, i.e., are prevalent infrequently in only few non-diversified countries.
Their determinants/risks include some familiar enemies of health and allies of poverty, such
as unsafe water, poor sanitation and hygiene, underweight, and indoor smoke from solid fuels
[20]. Many people in the developing world, particularly women and children, continue to suf-
fer from undernutrition. According to WHO [20] poverty is the main underlying determinant
of undernutrition, and 50-70% of the burden of (non-complex) communicable diseases like
diarrheal diseases, malaria, and lower respiratory infections in childhood is attributable to
undernutrition. Among adolescents and adults, undernutrition is also associated with adverse
pregnancy outcomes, which is one of the five lowest DCI disease sections in our dataset
(Table 1).
The descriptive findings in Fig 8 and the above discussion are also observable in Fig 9,
where we map the spatial variation in complex diseases. This figure shows the repartition of
the HCI across countries in 2016. We see rather clearly that disease complexity is unevenly
distributed in the world and that the most complex countries in terms of diseases seem to be
located in Europe, North America, and Australia—European countries, Australia, the US, and
Fig 9. Health complexity index across the world. Percentile repartition. Countries depicted in dark red have an HCI above the 80th percentile. Data
for 2016.
https://doi.org/10.1371/journal.pone.0244843.g009
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Canada belong to the set of countries with the highest HCI (> 80%). In contrast, most coun-
tries in Africa have much lower HCIs on average.
Regarding the evolution of HCI scores over time, Fig 10 depict the HCI scores by country
and for different sub-national regions of the world from 1990 to 2016. As observed in Fig 9 for
2016, the countries in Western Europe, North America, and Australasia have the highest HCIs
in the world and these scores remain stable over the period covered. Countries located in
High-income Asia Pacific, Southern Latin America, and Eastern Europe followed a similar pat-
tern. Amongst the high-HCI regions, Central Europe had the highest increase in the complex-
ity of its diseases. It gained 5 positions on average in the HCI ranking (from 34.3 in 1990 to
28.6 in 2016), with Poland climbing up to 20 positions between 1990 and 2016. In regions with
upper-middle HCIs in 2016, we observe a slight increase in the complexity of diseases, in par-
ticular for countries in East Asia, Caribbean, Central Latin America, and North Africa and
Middle East. They gained 1 to 3 positions on average in the HCI ranking between 1990 and
2016. On the other hand, the diseases of countries in Andean and Tropical Latin America,
and Central Asia are now less complex than in 1990. Central Asia for example, lost 11 posi-
tions, and Tropical Latin America 5 positions, between 1990 and 2016.
In contrast, the variation in HCI is stronger for countries with a lower-middle HCI in 2016.
Southeast and South Asia experienced a significant increase in the complexity of their diseases.
Countries in Southeast Asia ranked 129.4 on average in 1990 compared to 116.3 in 2016.
Myanmar, Malaysia, Mauritius Myanmar, Sri Lanka, Thailand, and Vietnam gained from 10
to 20 positions between 1990 and 2016. While countries in South Asia, such as Bangladesh
and Nepal, gained 8 positions on average in the period covered. On the other hand, the HCI
decreased in Oceania, mainly because of a strong decrease in Vanuatu (that lost 20 positions in
the HCI ranking), Kiribati (lost 10 positions) and Papua New Guinea (lost 8 positions), and in
Southern Sub-Saharan Africa, in particular South Africa. For countries with low HCI in 2016,
the index remains rather stable over time. We note a slight increase in health complexity for
Western Sub-Saharan Africa. Cameroon, for instance, gained 19 positions in the HCI ranking
between 1990 and 2016. In Central Sub-Saharan Africa, where the HCI scores are among the
lowests, we observe a decrease in health complexity over time. Indeed, countries such as Equa-
torial Guinea lost 11 positions in the HCI ranking, and Gabon 20 positions between 1990 and
2016.
In total, Fig 10 shows that changes over time are rather small. Hence, it seems that a coun-
try’s HCI tends to persist through time, which is to be expected for a metric of disease preva-
lence aggregated at the country level. This motivates the inclusion of the lagged value of the
HCI in the set of explanatory variables when exploring the link between economic develop-
ment and health complexity in the next section.
The effect of economic development on health complexity
We study the effect of economic development on health complexity using data on GDP per
capita (from the World Bank’s World Development Indicators) and the HCI (see Section
‘Methods’). Given the availability of controls, the sample covers a minimum of 168 developed
and developing countries over the period of 1992-2015. For more information, see S1 Appen-
dix: List of countries in regressions.
Regression analysis
In order to estimate the effect of economic development on the health complexity of countries,
we follow a fixed-effects two-stage least squares/instrumental variables (FE 2SLS/IV) strategy,
complemented with a difference Generalized Method of Moments (diff-GMM) approach. The
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Fig 10. Evolution of the health complexity index (HCI) between 1990 and 2016. The greyed out lines represent the
evolution of the HCI for each of the 195 countries. The colors depict different sub-national regions of the world
according to the Global Burden of Diseases’ classification. The colored lines display the yearly average of countries’
HCI and the labels the average of countries’ HCI rank in 1990 and 2016 by sub-national region.
https://doi.org/10.1371/journal.pone.0244843.g010
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regression analysis was performed with Stata/SE 16.1. We regress the baseline specification
described by the following equation:
HCIi;t ¼ rHCIi;t  1 þ b1GDPpci;t þ bkcontrolsi;t þ gi þ dt þ ui;t: ð7Þ
Here, the health complexity of country i in period t (HCIi,t) depends on the country’s level of
economic development in per capita terms (in logs), GDPpci,t. The lagged value of the depen-
dent variable on the right-hand side is included to capture persistence in health complexity.
The main variable of interest is GDPpc. The parameter β1 therefore measures the link between
income per capita and health complexity. As discussed above, the set of diseases in a country
does not increase monotonically in time. When countries become more developed, they are
more effective at fighting diseases therefore some diseases disappear. In order to account for
possible changes in the relation between income per capita and health complexity over the pro-
cess of economic development (turning point), we have experimented with the inclusion of
the quadratic specification of GDP per capita in the estimated equation. Our baseline results
(which are available upon request) do not confirm an U-shaped relationship between economic
development and health complexity. Additional potential covariates are included in the vector
controlsi,t. The γi’s denote a full set of country dummies and the δt’s denote a full set of time
effects that capture common shocks to the health complexity scores of all countries. The error
term ui,t captures all other omitted factors, with E(ui,t) = 0 for all i and t.
To examine the robustness of our results and to generalize our findings, we replicate our
analysis for additional/alternative control variables and substitute the HCI with the AHCI,
finding qualitatively similar results (see subsection).
Control variables. We include in the estimated equation a number of control variables
that are likely related to health complexity.
The proportion of nations’ populations over the age of 65 has been increasing in recent
years and will continue to rise in future as a result of longer life expectancy. Population age-
structure is a significant determinant of a nation’s health status, due to age-related diseases
(i.e., illnesses and conditions that occur more frequently in people as they get older). Examples
of age-related diseases include cardiovascular and cerebrovascular diseases, hypertension,
cancer, Parkinson’s disease, Alzheimer’s disease, osteoarthritis and osteoporosis. Demographic
factors such as age and sex are considered key covariates in the study of human health and
well-being, hence the percentage of old population (aged 65 and above, in logs) and the per-
centage of female population (in logs) are included in the set of control variables.
It has previously been shown that sex interacts with social, economic and biological deter-
minants to create different health outcomes for males and females. For example, [92] reviews
a large number of studies on the interaction between sex and the determinants and conse-
quences of chronic diseases, showing how these interactions result in different approaches to
prevention, treatment, and coping with illness.
In our analysis, we also control for the (log) percentage of urban population, urban. Accord-
ing to the World Health Organization (WHO), a large proportion of non-communicable dis-
eases is linked to risks related to the urban environment, such as physical inactivity and obesity,
cardiovascular and pulmonary diseases from transport-generated urban air pollution, ischemic
heart disease and cancers from household biomass energy use, asthma from indoor air pollu-
tion, and heat-related strokes and illnesses. In addition, communicable diseases such as tuber-
culosis, dengue fever, and many respiratory and diarrheal diseases result from unhealthy urban
environments (e.g. lack of adequate ventilation, unsafe water storage and poor waste manage-
ment, indoor air pollution, moldy housing interiors, poor sanitation). See [93].
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Industrialization, i.e., the structural transformation from agricultural to industrial produc-
tion also has a range of significant health implications [94–98]. We capture these implications
in our analysis by including the (log) value added of agriculture (% of GDP) and the (log) value
added ofmanufacturing (% of GDP) in the estimated equation.
To check the robustness of our baseline results, we replicate our analysis controlling also
for the human capital of the population by using total enrolment in tertiary education (in
logs). It is well established in the relevant literature that through education, people gain the
ability to be effective in their lives. They adopt healthier lifestyles and inspire their offspring to
do as well [99]. Individuals with higher levels of education also tend to have better socioeco-
nomic resources for a healthy lifestyle and a higher probability of living and working in healthy
environments [100, 101]. In addition, educated individuals tend to have lower exposure to
chronic stress [102]. Low educational attainment, on the other hand, is associated with a
shorter life expectancy, poor self-reported health, and a high prevalence of infectious and
chronic non-infectious diseases [103–106]. [107] and [108] review the relationships between
education and a wide variety of health measures. Furthermore, we re-estimate the baseline
model by substituting urban with population density (people per square km of land, in logs).
The variable CO2 (CO2 emissions in kg per 2010 $US of GDP) captures the effect of air pol-
lution on health, which has been the subject of numerous studies in recent years (for an exten-
sive review, see [109]).
Finally, health expenditure (log of total health spending in thousands of purchasing power
parity (PPP)-adjusted 2017 $US) is also included in the set of explanatory variables controlling
for the association between healthcare spending and health outcomes [110–117]
Data definitions, sources and summary statistics for the variables included in the analysis
are given in Table 2.
Instrumental variables. We estimate Eq (7) using different econometric methods. First,
we use fixed-effects OLS. However, fixed effects estimators do not necessarily identify the
effect of economic development on health complexity. The estimation of causal effects requires
exogenous sources of variation. While we do not have an ideal source of exogenous variation
recognized by previous studies, there are two promising potential instruments of economic
development that we adopt in our fixed-effects 2SLS/IV and diff-GMM analyses.
First, we use the KOF Swiss Economic Institute’s economic globalization index, character-
ized as the flows of goods, capital, and services, as well as information and perceptions that
accompany market exchanges [118]. Higher values reflect greater economic globalization.
The second instrument considered is the KOF Swiss Economic Institute’s political globali-
zation index, characterized by the number of embassies in a country, its membership in inter-
national organizations, its participation in UN security council missions and international
treaties. Higher values reflect greater political globalization.
There is extensive research documenting the positive relationship between globalization
and economic development and growth [118–122]. While we do not develop a theoretical
model of supporting the HCI in this paper, we expect that changes in the economic globaliza-
tion and political globalization indices have no direct effect on a country’s health complexity.
We predict that both indices of globalization impact the HCI only indirectly, through the
channel of economic development. This prediction is verified in our dataset by a series of sta-
tistical tests (see next section).
Regression results
In this section, we discuss the results of estimating Eq (7) with different econometric tech-
niques. Table 3 reports the results of fixed-effects ordinary least squares (FE-OLS) with time
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dummies, adding an additional variable from the set of controls in each step (column). In all
specifications, economic development has a positive relationship with health complexity, and
the control variables enter with the expected sign. The agriculture coefficient is negative, and
countries with a higher proportion of urban population exhibit greater health complexity.
The results depicted in Table 3 could only be interpreted as correlations. For a robust analy-
sis accounting for the potential endogeneity problem in the relationship under consideration
(discussed above), we use fixed-effects 2SLS/IV estimation techniques complemented with
diff-GMM estimations à la Arellano-Bond [123]. Table 4 presents our baseline results.
In columns (1)-(8), we estimate Eq (7) with FE 2SLS/IV regressions. We use time dummies
and robust standard errors (in parentheses). In all cases, GDPpc is a positive and statistically
significant predictor of health complexity. In fact, we find that an increase in GDP per capita of
10% is associated with an improvement of about 0.003 in the HCI (standard deviation: 1.004).
This positive impact of economic development on health complexity is robust to the inclusion
of control measures discussed in subsection 1. The statistically significant urban coefficient
implies that a higher proportion of urban population is associated with more complex
diseases.
In the fixed effects 2SLS/IV estimations we report: (a) the F-test for the joint significance of
the instruments in the first stage: the rule of thumb is to exceed 10, hence the test implies weak
significance [124]; (b) the Durbin-Wu-Hausmann (DWH) test for the endogeneity of regres-
sors: the null hypothesis that the IV regression is not required is rejected; (c) the Cragg-Donald
F-statistic (Weak-id), testing the relevance of the instruments in the first-stage regression: no
Table 2. Variable definitions, sources and summary statistics.
Variable Definition Source Mean Std.
Dev.
HCI Health Complexity Index. Authors’ calculations -0.006 1.004
HCI+ age-standardized Health Complexity Index. Authors’ calculations -0.008 1.008
GDPpc (log) GDP per capita, PPP (constant 2011 international $) World Development
Indicators
8.342 1.521
old (log) Population aged 65 and above (% of total) World Development
Indicators
1.764 0.667
female (log) Female population (% of total) World Development
Indicators
3.912 0.067
urban (log) Urban population (% of total) World Development
Indicators
3.871 0.519
agriculture (log) Agriculture, value added (% of GDP) World Development
Indicators
2.054 1.228
manufacturing (log) Manufacturing, value added (% of GDP) World Development
Indicators
2.407 0.591
education (log) Enrollment in secondary education, both sexes (total) World Development
Indicators
4.229 0.587
population density (log) Population density (people per sq. km of land area) World Development
Indicators
4.123 1.398
CO2 (log) CO2 emissions (kg per 2010 $US of GDP) World Bank -0.930 0.704





Actual flows (trade, foreign direct investment, stocks, portfolio investment, income payments to
foreign nationals), restrictions (hidden import barriers, mean tariff rate, taxes on international
trade, capital account restrictions). Higher values reflect greater economic globalization.
KOF Index of Globalization 54.462 16.234
political
globalization
Embassies in country, membership in international organizations, participation in UN security
council missions, international treaties. Higher values reflect greater political globalization.
KOF Index of Globalization 62.283 21.985
https://doi.org/10.1371/journal.pone.0244843.t002
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evidence of a low correlation between instruments and the endogenous regressor is found
after controlling for the exogenous regressors; (d) the Kleibergen-Paap Wald test (LM-weakid)
of weak identification: the null hypothesis that the model is weakly identified is rejected; (e)
the p-value for Hansen’s test of overidentification: the acceptance of the null indicates that the
overidentifying restrictions cannot be rejected.
In column (9) of Table 4 we report the diff-GMM estimations including year fixed effects
and robust standard errors. The results verify the previous findings both qualitatively and
quantitatively, i.e., the estimated coefficient of GDPpc implies an increase of 0.003 in the HCI
with a GDP per capita increase of 10%. Among the control variables, only the urban variable
has a statistically significant and positive sign. The values reported for AR(1) and AR(2) are
the p-values for first- and second-order autocorrelated disturbances. As expected, there is high
first-order autocorrelation and no evidence for significant second-order autocorrelation.
Hence, our test statistics hint at a proper specification.
In Tables 5 and 6, we investigate the robustness of our baseline findings. First, we substitute
the HCI with the age-standardized health complexity index (AHCI) maintaining the same set
of controls (and time dummies) as in the baseline specification. Second, we investigate whether
the positive impact of economic development on health complexity persists under additional
and/or alternative control measures (including time dummies). In all cases, the baseline results
remain qualitatively intact. In particular, the coefficient of GDPpc is positive and statistically
significant in the instrumented regressions (see Table 5; to save space, we only include the
first-stage estimated coefficients of the instruments—the results for the rest of the variables
are available upon request).
Table 6 starts from the baseline specification with the full set of controls [column (9) in
Table 4] and introduces additional variables or alternative measures for some of the previous
Table 3. The effect of economic development on health complexity: Fixed-effects OLS.
(1) (2) (3) (4) (5) (6)
HCIt−1 0.938��� 0.938��� 0.938��� 0.933��� 0.929��� 0.929���
(0.009) (0.009) (0.010) (0.010) (0.010) (0.010)
GDPpc 0.013��� 0.013��� 0.013��� 0.012��� 0.009�� 0.011���
(0.003) (0.003) (0.003) (0.003) (0.003) (0.004)
old -0.001 -0.001 0.002 0.000 0.002
(0.006) (0.006) (0.006) (0.007) (0.007)
female -0.014 -0.013 0.002 -0.006
(0.024) (0.024) (0.023) (0.024)






Observations 4,750 4,593 4,593 4,593 4,377 4,181
Countries 190 183 183 183 180 177
R-squared 0.873 0.874 0.874 0.875 0.872 0.872
Note: Dependent variable: Health Complexity Index (HCI). Main independent variable: GDP per capita in logs (GDPpc). Time fixed-effects are included in all
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controls. Specifically, in column (1), we add education (enrolment in secondary education in
logs). In column (2), we substitute the urban population variable with population density (peo-
ple per sq. km of land in logs). In columns (3) and (4), we employ (log) CO2 emissions (CO2
emissions, kg per 2010 $US of GDP) and (log) health expenditure (total health spending, thou-
sands of 2017 PPP adjusted $US), respectively. Finally, in column (5), we consider all of the
above variables together. Adding these controls in our estimations leaves the findings qualita-
tively and quantitatively intact.
Table 4. The effect of economic development on health complexity: Baseline results.
(1) (2) (3) (4) (5) (6) (7) (8) (9)
FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV diff-GMM
HCIt−1 0.926��� 0.927��� 0.927��� 0.923��� 0.923��� 0.922��� 0.922��� 0.921��� 0.814���
(0.010) (0.010) (0.010) (0.010) (0.010) (0.010) (0.011) (0.010) (0.061)
GDPpc 0.031��� 0.031��� 0.031��� 0.031��� 0.026�� 0.029��� 0.030� 0.027�� 0.032��
(0.011) (0.011) (0.011) (0.011) (0.011) (0.011) (0.017) (0.013) (0.013)
old -0.003 -0.002 -0.001 -0.003 -0.001 -0.002 -0.001 -0.005
(0.005) (0.005) (0.005) (0.006) (0.006) (0.006) (0.006) (0.017)
female -0.015 -0.015 -0.019 -0.029 -0.031 -0.026 0.029
(0.023) (0.023) (0.027) (0.028) (0.033) (0.029) (0.044)
urban 0.013 0.020��� 0.017�� 0.017�� 0.017�� 0.031�
(0.008) (0.008) (0.008) (0.009) (0.008) (0.018)
agriculture -0.003 -0.003 -0.002 -0.003 -0.002
(0.003) (0.003) (0.004) (0.003) (0.008)
manufacturing 0.002 0.002 0.002 -0.003
(0.002) (0.002) (0.002) (0.012)
Fist-stage results
economic globalization 0.003��� 0.003��� 0.003��� 0.003��� 0.004��� 0.003��� 0.005���
(0.001) (0.001) (0.001) (0.001) (0.000) (0.000) (0.000)
political globalization 0.004��� 0.004��� 0.004��� 0.004��� 0.004��� 0.005��� 0.006���
(0.001) (0.001) (0.001) (0.001) (0.000) (0.000) (0.000)
Observations 4,168 4,143 4,143 4,143 3,976 3,826 3,826 3,926 3,652
Countries 171 170 170 170 170 168 168 173 168
F-test 37.24 37.05 36.31 39.93 56.26 61.41 79.18 76.56
DWH-test 2.978 2.911 2.785 3.073 2.500 2.646 1.304 1.523
Weak-id 59.73 54.25 54.88 56.82 97.43 107.0 104.3 152.6
LM-weakid 71.12 70.95 69.68 75.01 109.7 116.3 72.90 73.98
Hansen (p-value) 0.590 0.699 0.676 0.897 1.000 0.904
AR(1) 0.000
AR(2) 0.475
Note: Dependent variable: Health Complexity Index (HCI). Main independent variable: GDP per capita in logs (GDPpc). Columns (1)-(8): Fixed-effects 2SLS/IV; HCI is
instrumented: To save space, we only include the first-stage estimated coefficients of the instruments. The results for the rest of the variables are available upon request.
Column (9): One-step diff-GMM. All regressions include time dummies. Robust standard errors are in parentheses. F-test gives the F-statistic for the joint significance
of the instruments in the first stage. DWH-test is the Durbin-Wu-Hausman test of endogeneity of the regressors. Weak-id gives the Cragg-Donald F-statistic for weak
identification. LM-weakid gives the Kleibergen-Paap Wald test of weak identification. Hansen (p-value) gives the p-value of the Hansen test of overidentification. AR(1)
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The above analysis suggests that economically developed countries tend to exhibit more
complex disease structures. Furthermore, exploiting the temporal variation in the data, the
fixed-effects 2SLS/IV analysis and the difference GMM estimators reveal a positive, statistically
significant, and robust impact of economic development on health complexity.
Economic development and disease complexity
The economic complexity methodology provides a useful toolbox that allows us to compute
indices that quantify the complexity of both countries and diseases. The DCI quantifies the
complexity of countries’ diseases according to their rate of prevalence worldwide.
Table 5. The effect of economic development on health complexity: AHCI.
(1) (2) (3) (4)
FE 2SLS/IV FE 2SLS/IV FE 2SLS/IV diff-GMM
AHCIt−1 0.923��� 0.925��� 0.919��� 0.828���
(0.011) (0.012) (0.011) (0.114)
GDPpc 0.037��� 0.033�� 0.041��� 0.024�
(0.011) (0.015) (0.014) (0.013)
female -0.028 -0.021 -0.037 0.030
(0.027) (0.034) (0.031) (0.040)
urban 0.009 0.010 0.007 0.011
(0.007) (0.008) (0.008) (0.023)
agriculture 0.002 0.001 0.003 0.008
(0.003) (0.004) (0.004) (0.010)
manufacturing 0.002 0.002 0.003 -0.013
(0.002) (0.002) (0.002) (0.011)
Fist-stage results
economic globalization 0.004��� 0.005���
(0.000) (0.000)
political globalization 0.004��� 0.005���
(0.000) (0.000)
Observations 3,826 3,826 3926 3,652
Countries 168 168 173 168
F-test 67.39 101.5 71.22
DWH-test 6.055 2.200 4.548
Weak-id 116.2 136.4 138.9




Note: Dependent variable: Age-standardized Health Complexity Index (AHCI). Main independent variable: GDP per capita in logs (GDPpc). Columns (1)-(3): Fixed-
effects 2SLS/IV; AHCI is instrumented: To save space, we only include the first-stage estimated coefficients of the instruments. The results for the rest of the variables are
available upon request. Column (4): One-step diff-GMM. All regressions include time dummies. Robust standard errors are in parentheses. F-test gives the F-statistic for
the joint significance of the instruments in the first stage. DWH-test is the Durbin-Wu-Hausman test of endogeneity of the regressors. Weak-id gives the Cragg-Donald
F-statistic for weak identification. LM-weakid gives the Kleibergen-Paap Wald test of weak identification. Hansen (p-value) gives the p-value of the Hansen test of
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Using the economic complexity methodology, [56] recently introduced a measure that asso-
ciates products with income inequality and showed how the development of new products is
associated with changes in income inequality. Here, to decompose economic development at
the disease level, we introduce a measure that links a disease to the average income per capita
of the countries in which the disease is prevalent i.e., an estimate of the expected income per
capita related to different diseases. In this way, we illustrate how disease complexity is being
affected by the level of economic development and quantify the relationship between coun-
tries’ income per capita and the complexity of their diseases.
Following the methodology in [56], we define the Disease-Income Complexity Index (DICI)
and decompose the relationship between the DCI and the DICI for the diseases in our sample
of countries. We also computed the Age-standardized Disease-Income Complexity Index
ADICI and investigated its relationship with the ADCI, finding similar results.
Table 6. The effect of economic development on health complexity: Robustness checks.
(1) (2) (3) (4) (5)
diff-GMM diff-GMM diff-GMM diff-GMM diff-GMM
HCIt−1 0.752��� 0.871��� 0.812��� 0.920��� 0.666���
(0.059) (0.046) (0.063) (0.040) (0.062)
GDPpc 0.031� 0.031��� 0.024� 0.042��� 0.038�
(0.016) (0.011) (0.013) (0.016) (0.020)
old -0.022 -0.010 0.004 -0.002 -0.005
(0.024) (0.017) (0.018) (0.016) (0.029)
female 0.053 0.018 0.053 -0.068 -0.170
(0.050) (0.051) (0.045) (0.047) (0.124)
urban 0.055 0.013 0.022
(0.035) (0.017) (0.023)
agriculture 0.007 -0.001 0.003 0.001 0.015
(0.009) (0.006) (0.009) (0.008) (0.011)
manufacturing 0.008 -0.003 -0.015 0.014 0.020
(0.012) (0.011) (0.010) (0.011) (0.014)
education -0.003 0.026
(0.011) (0.017)




health expenditure -0.006 -0.012
(0.012) (0.018)
Observations 2,347 3,642 3,470 3,158 1,936
Countries 161 168 168 168 158
AR(1) 0.000 0.000 0.000 0.000 0.000
AR(2) 0.395 0.505 0.621 0.525 0.274
Note: Dependent variable: Health Complexity Index (HCI). Main independent variable: GDP per capita in logs (GDPpc). Regression analysis: One-step diff-GMM. All
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The disease-income complexity index
Assuming that we have information for l countries and k diseases, we can fill the (l × k) matrix
M so that its matrix elementMcd = 1 if country c has an RDD in disease d, and zero otherwise
(see Section ‘The relative disease disadvantage’). Our dataset contains information for 195
developed and developing countries and for 196 diseases from 1990 to 2016.






where Xcd is the number of cases per 100,000 population for disease d in country c, while ∑d0
Xcd0 is the number of cases of all diseases in country c. If GDPc is the (log) GDP per capita of







where Nd = ∑c Mcd scd is a normalization factor.
The DICI is defined at the disease level as the average level of (log) GDP per capita of the
countries that have an RDD in disease d, weighted by the disease’s importance in each coun-
try’s pool of diseases. Using the (log) PPP GDP per capita (constant 2011 international $) from
the World Bank’s World Development Indicators for the countries in our sample, we calculate
the above index for every year in the period of 1990-2016.
Table 7 lists the five diseases with the highest and lowest average DICI values during the
period of 1990-2016. It is evident that higher economic development is associated with more
complex diseases such as motor neuron disease and malignant skin melanoma. At the other
end of the spectrum, less complex diseases such as acute hepatitis E and malaria are associated
with low levels of income per capita.
Table 7. List of the five diseases with the highest and lowest DICI values during the period of 1990-2016.
code disease name disease section DICI DCI
Highest DICI
554 Motor neuron disease Neurological disorders 4.55 1.025
459 Malignant skin melanoma Neoplasms 4.52 1.210
573 Anorexia nervosa Mental disorders 4.49 0.818
483 Mesothelioma Neoplasms 4.49 1.041
485 Non-Hodgkin’s lymphoma Neoplasms 4.48 1.057
Lowest DICI
404 Acute hepatitis E Other infectious diseases 2.89 -1.707
345 Malaria Neglected tropical diseases and malaria 2.86 -2.045
353 Cystic echinococcosis Neglected tropical diseases and malaria 2.84 -1.383
370 Maternal obstructed labor and uterine rupture Maternal and neonatal disorders 2.80 -1.957
359 Rabies Neglected tropical diseases and malaria 2.76 -1.840
Notes: DICI: Disease-Income Complexity Index; DCI: Disease Complexity Index; Average values for 1990-2016
https://doi.org/10.1371/journal.pone.0244843.t007
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Linking economic development and disease complexity
In this subsection, we test the existence of a bivariate relationship between the DCI and the
DICI. Thus, we calculate Pearson’s correlation coefficient for DICI against DCI. If such an
association exists, it should allow us to derive expectations about whether disease complexity
can be associated with economic development and verify, with disease-level data, the statisti-
cally significant and positive relationship between health complexity and economic develop-
ment that we found above (Section 1). The correlation coefficient for the relationship between
the average values of the DICI and the DCI for the period of 1990-2016 is ρ = 0.96 ± 0.01 with
a p-value <2.2 × 10−16.
In Fig 11, we present the scatter-plot of the relationship between the DICI and the DCI for
the 196 diseases in our dataset (average values for 1990-2016), together with the fitted linear
model. The slope of the linear fit is the corresponding correlation coefficient.
The statistically significant positive correlation between the DICI and the DCI indicates
that more complex diseases are associated with more developed countries, as measured by the
Fig 11. DICI against DCI. The solid line represents the fit of a linear model and the dashed line a 95% prediction interval based on the fitted linear
model.
https://doi.org/10.1371/journal.pone.0244843.g011
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(log) GDP per capita. This allows us to understand which sets of diseases are linked to better
overall economic performance, based on their complexity.
In Table 8, we run panel regressions between the DCI and DICI. The results show that the
relationship between the DCI and the DICI is the outcome of the correlations both between
diseases (regression on group means) and within diseases (fixed-effects regression with time
dummies and standard errors adjusted for disease clusters). Running panel regressions in this
way allows us to exploit both the time-series and cross-sectional information in the data and in
our case suggests that the positive association of economic development with the complexity
of diseases is due to changes in the structure of the disease space towards more complex dis-
eases across time (the disease complexity increases over time) and between diseases (the dis-
ease complexity increases in relative terms).
Conclusions
Our analysis illustrates that the development of nations conditions the structure of the disease
space. Following the economic complexity methodology, we developed the HCI (DCI), which
quantifies the network representation of the co-occurrence of diseases. In a dynamic panel
data setting, we showed that there is a positive relationship between a country’s economic
development, measured by the GDP per capita, and its level of health complexity, i.e., the
‘structural’ composition of its pool of diseases. Specifically, more complex diseases tend to be
prevalent in populations with a higher income per capita.
Explicitly, the HCI and DCI reveal the following pattern across countries: High-DCI dis-
eases, i.e., the non-ubiquitous diseases that tend to be prevalent in the more disease-diversified
(high-HCI) countries, tend to be non-communicable diseases. Moreover, high-HCI countries,
which are the countries with RDD in high-DCI diseases, tend to be richer. Low-DCI diseases,
i.e., the non-ubiquitous diseases that tend to be prevalent in the less-diversified (low-HCI)
countries, tend to be communicable diseases. Moreover, low-HCI countries, which are the
countries with RDD in low-DCI diseases, tend to be poorer.
In addition, we built the DICI, which links a disease to the average level of income per cap-
ita of the countries in which the disease is prevalent, and illustrate how disease complexity is
related to economic development. Specifically, we showed how changes in GDP per capita are
associated with more high-DCI diseases. The temporal variation of the above indices is impor-
tant from a policy perspective. Using the HCI and DCI, it is possible to design policies aimed
Table 8. Disease-income complexity index and the complexity of diseases.
(1) (2)
DCI DCI






Notes: DICI: Disease-Income Complexity Index; DCI: Disease Complexity Index. Country and time dummies are
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at improving the recognition, visibility, and traceability of high-DCI diseases across the globe
and through time (e.g., by developing a classification system for all health information sys-
tems). These indices can also be used as tools for the development of national plans and the
establishment of knowledge networks for complex diseases. Furthermore, the DICI could be
used to design a health expenditure reallocation policy promoting health activities and services
associated with the prevention of complex diseases.
In sum, this study employs the economic complexity methodology to compute two new
metrics that quantify the disease space of countries. These unified measures can be valuable
tools to monitor, study the determinants, and measuring the impact of public policies on the
evolution of countries’ structure of diseases and the distribution of diseases worldwide. The
topic of economic complexity is a rather new one, and its use in health economics is so far
rather limited. By focusing on the topic of disease complexity, our contribution lies in bridging
the health economics literature with the literature that highlights economic complexity as a
powerful paradigm in understanding key issues in economics, geography, innovation studies,
and other social sciences.
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16. Punnett L. Prüss-Ütün A. Nelson D. I. Fingerhut M. A. Leigh J. Tak S, et al. Estimating the global bur-
den of low back pain attributable to combined occupational exposures. American journal of industrial
medicine. 2005; 48:459–469. https://doi.org/10.1002/ajim.20232 PMID: 16299708
17. Wang Q. Tapia-Granados J. S. Economic growth and mental health in 21st century China. Social Sci-
ence & Medicine. 2019; 220:387–395. https://doi.org/10.1016/j.socscimed.2018.11.031
18. Goh K.-I. Cusick M. E. Valle D. Childs B. Vidal M. Barabási A.-L. The human disease network, Pro-
ceedings of the National Academy of Sciences. 2007; 104:8685–8690. URL: https://www.pnas.org/
content/104/21/8685
19. Hidalgo C. A. Blumm N. Barabási A.-L. Christakis N. A. A dynamic network approach for the study of
human phenotypes. PLOS Computational Biology. 2009; 5:1–11. URL: https://doi.org/10.1371/
journal.pcbi.1000353
20. WHO, The world health report 2002: reducing risks, promoting healthy life, World Health Organization,
2002.
21. Cawley, J. Ruhm, J. C. Chapter Three—The Economics of Risky Health Behaviors, volume 2, Else-
vier, 2011, 95-199 URL: http://www.sciencedirect.com/science/article/pii/B9780444535924000037/
22. Hausmann, R. Klinger, B. Structural transformation and patterns of comparative advantage in the
product space 2006.
23. Ngai L. R. Pissarides C. A. Structural change in a multisector model of growth, American economic
review. 2007; 97:429–443. https://doi.org/10.1257/aer.97.1.429
PLOS ONE Health complexity
PLOS ONE | https://doi.org/10.1371/journal.pone.0244843 January 7, 2021 30 / 35
24. Gollin D. Parente S. Rogerson R. The role of agriculture in development. American Economic Review.
2002; 92:160–164. https://doi.org/10.1257/000282802320189177
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